{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:10Z","timestamp":1794072970971,"version":"4.8.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08-HL-146991"],"award-info":[{"award-number":["K08-HL-146991"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32-HL-007439"],"award-info":[{"award-number":["T32-HL-007439"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32-HL-007971"],"award-info":[{"award-number":["T32-HL-007971"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51296-8","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:41:53Z","timestamp":1724402513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Anna R.","family":"Sternberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2284-352X","authenticated-orcid":false,"given":"Cristina","family":"Martos-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1559","authenticated-orcid":false,"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"51296_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.blre.2004.02.003","volume":"19","author":"PJ Fay","year":"2005","unstructured":"Fay, P. J. & Jenkins, P. V. Mutating factor VIII: lessons from structure to function. Blood Rev. 19, 15\u201327 (2005).","journal-title":"Blood Rev."},{"key":"51296_CR2","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci, P. M. & Tuddenham, E. G. The hemophilias-from royal genes to gene therapy. N. Engl. J. Med. 344, 1773\u20131779 (2001).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR3","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","volume":"7","author":"P Agosti","year":"2023","unstructured":"Agosti, P. et al. Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A. Blood Adv. 7, 7209\u20137215 (2023).","journal-title":"Blood Adv."},{"key":"51296_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson, M. J. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med. 357, 535\u2013544 (2007).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu, J. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N. Engl. J. Med. 379, 811\u2013822 (2018).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George, L. A. et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N. Engl. J. Med. 385, 1961\u20131973 (2021).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu, J. et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N. Engl. J. Med. 388, 694\u2013705 (2023).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR8","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1182\/blood-2023-179422","volume":"142","author":"TJ Harrington","year":"2023","unstructured":"Harrington, T. J. et al. Four-year follow-up of the alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia \u0391. Blood 142, 3627 (2023).","journal-title":"Blood"},{"key":"51296_CR9","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1182\/blood-2023-180803","volume":"142","author":"P Chowdary","year":"2023","unstructured":"Chowdary, P. et al. AC. GO-8: stable expression of factor VIII over 5 years following adeno-associated gene transfer in subjects with hemophilia A using a novel human factor VIII variant. Blood 142, 3624 (2023).","journal-title":"Blood"},{"key":"51296_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi, K. J. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N. Engl. J. Med. 382, 29\u201340 (2020).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1056\/NEJMe2212347","volume":"388","author":"LA George","year":"2023","unstructured":"George, L. A. Hemophilia A gene therapy - some answers, more questions. N. Engl. J. Med. 388, 761\u2013763 (2023).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR12","doi-asserted-by":"crossref","unstructured":"Symington, E. et al. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment. Haemophilia 30, 320\u2013330 (2024).","DOI":"10.1111\/hae.14936"},{"key":"51296_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","volume":"74","author":"BJ Samelson-Jones","year":"2023","unstructured":"Samelson-Jones, B. J. & George, L. A. Adeno-associated virus gene therapy for hemophilia. Annu Rev. Med 74, 231\u2013247 (2023).","journal-title":"Annu Rev. Med"},{"key":"51296_CR14","doi-asserted-by":"crossref","unstructured":"Leavitt, A. D. et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the Phase 1\/2 Alta study. Blood 143, 796\u2013806 (2023).","DOI":"10.1182\/blood.2022018971"},{"key":"51296_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood.2019004334","volume":"136","author":"S Ferriere","year":"2020","unstructured":"Ferriere, S. et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood 136, 740\u2013748 (2020).","journal-title":"Blood"},{"key":"51296_CR16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","volume":"12","author":"BJ Samelson-Jones","year":"2019","unstructured":"Samelson-Jones, B. J. & Arruda, V. R. Protein-engineered coagulation factors for hemophilia gene therapy. Mol. Ther. Methods Clin. Dev. 12, 184\u2013201 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","volume":"361","author":"P Simioni","year":"2009","unstructured":"Simioni, P. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N. Engl. J. Med. 361, 1671\u20131675 (2009).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR18","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215\u20132227 (2017).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe, S. W. et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N. Engl. J. Med 388, 706\u2013718 (2023).","journal-title":"N. Engl. J. Med"},{"key":"51296_CR20","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1182\/blood.2020007562","volume":"137","author":"AR Wilhelm","year":"2021","unstructured":"Wilhelm, A. R. et al. Activated protein C has a regulatory role in factor VIII function. Blood 137, 2532\u20132543 (2021).","journal-title":"Blood"},{"key":"51296_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2014-02-555656","volume":"125","author":"L Leong","year":"2015","unstructured":"Leong, L. et al. Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models. Blood 125, 392\u2013398 (2015).","journal-title":"Blood"},{"key":"51296_CR22","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1073\/pnas.94.22.11851","volume":"94","author":"SW Pipe","year":"1997","unstructured":"Pipe, S. W. & Kaufman, R. J. Characterization of genetically engineered inactivation-resistant coagulation factor VIIIa. Proc. Natl Acad. Sci. USA 94, 11851\u201311856 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51296_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/0003-9861(87)90037-3","volume":"252","author":"FJ Walker","year":"1987","unstructured":"Walker, F. J., Chavin, S. & Fay, P. Inactivation of FVIII by activated protein C and protein S. Arch. Biochem. Biophys. 252, 322\u2013328 (1987).","journal-title":"Arch. Biochem. Biophys."},{"key":"51296_CR24","doi-asserted-by":"publisher","first-page":"20139","DOI":"10.1016\/S0021-9258(18)54901-2","volume":"266","author":"PJ Fay","year":"1991","unstructured":"Fay, P. J., Smudzin, T. M. & Walker, F. J. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. J. Biol. Chem. 266, 20139\u201320145 (1991).","journal-title":"J. Biol. Chem."},{"key":"51296_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38106-3","volume":"14","author":"A Gonzalez-Sandoval","year":"2023","unstructured":"Gonzalez-Sandoval, A. et al. The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner. Nat. Commun. 14, 2448 (2023).","journal-title":"Nat. Commun."},{"key":"51296_CR26","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/bloodadvances.2021006359","volume":"6","author":"TS Lundgren","year":"2022","unstructured":"Lundgren, T. S., Denning, G., Stowell, S. R., Spencer, H. T. & Doering, C. B. Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice. Blood Adv. 6, 2628\u20132645 (2022).","journal-title":"Blood Adv."},{"key":"51296_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80\u201386 (2010).","journal-title":"Mol. Ther."},{"key":"51296_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.omtm.2021.12.004","volume":"24","author":"CR Sihn","year":"2022","unstructured":"Sihn, C. R. et al. Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers. Mol. Ther. Methods Clin. Dev. 24, 142\u2013153 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/hum.2022.050","volume":"33","author":"NT Tran","year":"2022","unstructured":"Tran, N. T. et al. Human and insect cell-produced recombinant adeno-associated viruses show differences in genome heterogeneity. Hum. Gene Ther. 33, 371\u2013388 (2022).","journal-title":"Hum. Gene Ther."},{"key":"51296_CR30","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","volume":"30","author":"B Handyside","year":"2022","unstructured":"Handyside, B. et al. Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells. Mol. Ther. 30, 3570\u20133586 (2022).","journal-title":"Mol. Ther."},{"key":"51296_CR31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14916","volume":"30","author":"YB Ismail AM","year":"2024","unstructured":"Ismail AM, Y. B. et al. Human liver biopsy analysis reveals lower RNA transcription may contribute to a decline in FVIII levels following AAV5-hFVIII-SQ gene therapy. Haemophilia 30, 18 (2024).","journal-title":"Haemophilia"},{"key":"51296_CR32","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","volume":"18","author":"S Fong","year":"2020","unstructured":"Fong, S. et al. Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter. Mol. Ther. Methods Clin. Dev. 18, 620\u2013630 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","volume":"28","author":"S Fong","year":"2022","unstructured":"Fong, S. et al. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat. Med. 28, 789\u2013797 (2022).","journal-title":"Nat. Med."},{"key":"51296_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.63","volume":"3","author":"I Zolotukhin","year":"2016","unstructured":"Zolotukhin, I. et al. Potential for cellular stress response to hepatic factor VIII expression from AAV vector. Mol. Ther. Methods Clin. Dev. 3, 16063 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR35","doi-asserted-by":"publisher","first-page":"16064","DOI":"10.1038\/mtm.2016.64","volume":"3","author":"AM Lange","year":"2016","unstructured":"Lange, A. M., Altynova, E. S., Nguyen, G. N. & Sabatino, D. E. Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. Mol. Ther. Methods Clin. Dev. 3, 16064 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR36","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood.2019002867","volume":"135","author":"J Poothong","year":"2020","unstructured":"Poothong, J. et al. Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum. Blood 135, 1899\u20131911 (2020).","journal-title":"Blood"},{"key":"51296_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nri2359","volume":"8","author":"DJ Todd","year":"2008","unstructured":"Todd, D. J., Lee, A. H. & Glimcher, L. H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat. Rev. Immunol. 8, 663\u2013674 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"51296_CR38","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/jth.12189","volume":"11","author":"JC Cardenas","year":"2013","unstructured":"Cardenas, J. C. et al. Murine models do not recapitulate the pathophysiology of age-related venous thrombosis in humans. J. Thromb. Haemost. 11, 990\u2013992 (2013).","journal-title":"J. Thromb. Haemost."},{"key":"51296_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","volume":"90","author":"B Dahlback","year":"1993","unstructured":"Dahlback, B., Carlsson, M. & Svensson, P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl Acad. Sci. USA 90, 1004\u20131008 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51296_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/369064a0","volume":"369","author":"RM Bertina","year":"1994","unstructured":"Bertina, R. M. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64\u201367 (1994).","journal-title":"Nature"},{"key":"51296_CR41","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1182\/blood.V96.13.4222","volume":"96","author":"J Cui","year":"2000","unstructured":"Cui, J. et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 96, 4222\u20134226 (2000).","journal-title":"Blood"},{"key":"51296_CR42","doi-asserted-by":"crossref","unstructured":"Jalbert, L. R. et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J. Clin. Invest. 102, 1481\u20131488 (1998).","DOI":"10.1172\/JCI3011"},{"key":"51296_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1056\/NEJM198403013100904","volume":"310","author":"U Seligsohn","year":"1984","unstructured":"Seligsohn, U. et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N. Engl. J. Med. 310, 559\u2013559 (1984).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR44","doi-asserted-by":"publisher","first-page":"e0154857","DOI":"10.1371\/journal.pone.0154857","volume":"11","author":"JM Staber","year":"2016","unstructured":"Staber, J. M. & Pollpeter, M. J. Shortened lifespan and lethal hemorrhage in a hemophilia A mouse model. PLoS ONE 11, e0154857 (2016).","journal-title":"PLoS ONE"},{"key":"51296_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1006\/geno.1993.1200","volume":"16","author":"B Elder","year":"1993","unstructured":"Elder, B., Lakich, D. & Gitschier, J. Sequence of the murine factor VIII cDNA. Genomics 16, 374\u2013379 (1993).","journal-title":"Genomics"},{"key":"51296_CR46","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S. et al. AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519\u20132530 (2017).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR47","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/blood-2003-05-1519","volume":"102","author":"HV Yarovoi","year":"2003","unstructured":"Yarovoi, H. V. et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 102, 4006\u20134013 (2003).","journal-title":"Blood"},{"key":"51296_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/jth.13543","volume":"15","author":"GN Nguyen","year":"2017","unstructured":"Nguyen, G. N. et al. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A. J. Thromb. Haemost. 15, 110\u2013121 (2017).","journal-title":"J. Thromb. Haemost."},{"key":"51296_CR49","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi, F. et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111, 1347\u20131356 (2003).","journal-title":"J. Clin. Invest."},{"key":"51296_CR50","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","volume":"116","author":"JD Finn","year":"2010","unstructured":"Finn, J. D. et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116, 5842\u20135848 (2010).","journal-title":"Blood"},{"key":"51296_CR51","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2516.2010.02397.x","volume":"17","author":"M Qadura","year":"2011","unstructured":"Qadura, M. et al. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb\/c and C57BL\/6 haemophilia A mice. Haemophilia 17, 288\u2013295 (2011).","journal-title":"Haemophilia"},{"key":"51296_CR52","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1182\/blood-2012-02-412361","volume":"120","author":"SL Meeks","year":"2012","unstructured":"Meeks, S. L. et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 120, 2512\u20132520 (2012).","journal-title":"Blood"},{"key":"51296_CR53","unstructured":"White, G. C., 2nd, Marder, V. J., Schulman, S., Aird, W. C. & Bennett, J. S. in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (eds. White, G. C., 2nd, Marder, V. J., Schulman, S., Aird, W. C. & Bennett, J.S.) 103\u2013109 (Lippincott Williams & Wilkins, 2013)."},{"key":"51296_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1055\/s-0038-1648849","volume":"72","author":"S Rosen","year":"1994","unstructured":"Rosen, S., Johansson, K., Lindberg, K. & Dahlback, B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group. Thromb. Haemost. 72, 255\u2013260 (1994).","journal-title":"Thromb. Haemost."},{"key":"51296_CR55","unstructured":"Chromogenix. COATEST\u2122 APC\u2122 Resistance [package insert] (2016)."},{"key":"51296_CR56","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","volume":"93","author":"MC de Visser","year":"1999","unstructured":"de Visser, M. C., Rosendaal, F. R. & Bertina, R. M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 93, 1271\u20131276 (1999).","journal-title":"Blood"},{"key":"51296_CR57","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/00001721-199611000-00003","volume":"7","author":"MA Laffan","year":"1996","unstructured":"Laffan, M. A. & Manning, R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul. Fibrinolysis 7, 761\u2013765 (1996).","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"51296_CR58","unstructured":"Food and Drug Administration (FDA), C., Tissue, and Gene Therapies Advisory Committee (CTGTAC). Toxicity Risks of Adeno-associated Virus (AAV) Vectors for Gene Therapy (GT) (2021). https:\/\/www.fda.gov\/media\/151599\/download."},{"key":"51296_CR59","doi-asserted-by":"crossref","unstructured":"Pekrun, K. et al. Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques. Mol. Ther. 32, 2064\u20132079 (2024).","DOI":"10.1016\/j.ymthe.2024.05.005"},{"key":"51296_CR60","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","volume":"18","author":"NG Rumachik","year":"2020","unstructured":"Rumachik, N. G. et al. Methods matter: standard production platforms for recombinant aav produce chemically and functionally distinct vectors. Mol. Ther. Methods Clin. Dev. 18, 98\u2013118 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR61","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2019.05.010","volume":"30","author":"EDR Arrojo","year":"2019","unstructured":"Arrojo, E. D. R. et al. Age mosaicism across multiple scales in adult tissues. Cell Metab. 30, 343\u2013351 e343 (2019).","journal-title":"Cell Metab."},{"key":"51296_CR62","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood.V93.1.176","volume":"93","author":"SW Pipe","year":"1999","unstructured":"Pipe, S. W., Eickhorst, A. N., McKinley, S. H., Saenko, E. L. & Kaufman, R. J. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 93, 176\u2013183 (1999).","journal-title":"Blood"},{"key":"51296_CR63","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.V97.3.685","volume":"97","author":"SW Pipe","year":"2001","unstructured":"Pipe, S. W., Saenko, E. L., Eickhorst, A. N., Kemball-Cook, G. & Kaufman, R. J. Hemophilia A mutations associated with 1-stage\/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 97, 685\u2013691 (2001).","journal-title":"Blood"},{"key":"51296_CR64","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1055\/s-0037-1613302","volume":"88","author":"WH Hakeos","year":"2002","unstructured":"Hakeos, W. H. et al. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage\/two-stage activity discrepancy. Thromb. Haemost. 88, 781\u2013787 (2002).","journal-title":"Thromb. Haemost."},{"key":"51296_CR65","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1182\/blood.V63.6.1303.1303","volume":"63","author":"P Lollar","year":"1984","unstructured":"Lollar, P., Knutson, G. & Fass, D. Stabilisation of thrombin activated porcine Factor VIII:C by Factor IXa and phospholipid. Blood 63, 1303\u20131308 (1984).","journal-title":"Blood"},{"key":"51296_CR66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1055\/s-0037-1615833","volume":"82","author":"PJ Fay","year":"1999","unstructured":"Fay, P. J. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb. Haemost. 82, 193\u2013200 (1999).","journal-title":"Thromb. Haemost."},{"key":"51296_CR67","doi-asserted-by":"publisher","first-page":"23652","DOI":"10.1016\/S0021-9258(18)35888-5","volume":"267","author":"P Lollar","year":"1992","unstructured":"Lollar, P., Parker, E. T. & Fay, P. J. Coagulant properties of hybrid human\/porcine factor VIII molecules. J. Biol. Chem. 267, 23652\u201323657 (1992).","journal-title":"J. Biol. Chem."},{"key":"51296_CR68","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1074\/jbc.271.8.3982","volume":"271","author":"LM Regan","year":"1996","unstructured":"Regan, L. M. et al. Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase. J. Biol. Chem. 271, 3982\u20133987 (1996).","journal-title":"J. Biol. Chem."},{"key":"51296_CR69","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1182\/blood.V95.5.1714.005k40_1714_1720","volume":"95","author":"LM O\u2019Brien","year":"2000","unstructured":"O\u2019Brien, L. M., Mastri, M. & Fay, P. J. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 95, 1714\u20131720 (2000).","journal-title":"Blood"},{"key":"51296_CR70","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0022-3476(84)80013-X","volume":"105","author":"RH Sills","year":"1984","unstructured":"Sills, R. H., Marlar, R. A., Montgomery, R. R., Deshpande, G. N. & Humbert, J. R. Severe homozygous protein C deficiency. J. Pediatrics 105, 409\u2013409 (1984).","journal-title":"J. Pediatrics"},{"key":"51296_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jth.14343","volume":"17","author":"IM Rietveld","year":"2019","unstructured":"Rietveld, I. M. et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J. Thromb. Haemost. 17, 99\u2013109 (2019).","journal-title":"J. Thromb. Haemost."},{"key":"51296_CR72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJM200008173430702","volume":"343","author":"PA Kyrle","year":"2000","unstructured":"Kyrle, P. A. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N. Engl. J. Med. 343, 457\u2013462 (2000).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR73","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo, M. C. et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N. Engl. J. Med. 386, 1013\u20131025 (2022).","journal-title":"N. Engl. J. Med."},{"key":"51296_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","volume":"129","author":"SG Polderdijk","year":"2017","unstructured":"Polderdijk, S. G. et al. Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood 129, 105\u2013113 (2017).","journal-title":"Blood"},{"key":"51296_CR75","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2023-179969","volume":"142","author":"HJ Baglin T","year":"2023","unstructured":"Baglin T, H. J., Koch, A., Mocanu, I. & Makhaldiani, L. Serpin-PC in persons with severe hemophilia (PwH): updated results from a multicenter multi-part, first-in-human study. Blood 142, 2619 (2023).","journal-title":"Blood"},{"key":"51296_CR76","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/ATVBAHA.111.244608","volume":"32","author":"JA Diaz","year":"2012","unstructured":"Diaz, J. A. et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb. Vasc. Biol. 32, 556\u2013562 (2012).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"51296_CR77","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","volume":"81","author":"DD Pittman","year":"1993","unstructured":"Pittman, D. D. et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted FVIII. Blood 81, 2925\u20132935 (1993).","journal-title":"Blood"},{"key":"51296_CR78","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omtm.2021.11.005","volume":"24","author":"L Elkouby","year":"2022","unstructured":"Elkouby, L. et al. Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A. Mol. Ther. Methods Clin. Dev. 24, 20\u201329 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"51296_CR79","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymthe.2005.02.021","volume":"12","author":"JF Wright","year":"2005","unstructured":"Wright, J. F. et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol. Ther. 12, 171\u2013178 (2005).","journal-title":"Mol. Ther."},{"key":"51296_CR80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1525-0016(02)00019-9","volume":"7","author":"JM Sommer","year":"2003","unstructured":"Sommer, J. M. et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther. 7, 122\u2013128 (2003).","journal-title":"Mol. Ther."},{"key":"51296_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/srep11315","volume":"5","author":"M Hashimoto","year":"2015","unstructured":"Hashimoto, M. & Takemoto, T. Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR\/Cas9-based genome editing. Sci. Rep. 5, 11315 (2015).","journal-title":"Sci. Rep."},{"key":"51296_CR82","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jtha.2023.04.012","volume":"21","author":"GN Nguyen","year":"2023","unstructured":"Nguyen, G. N. et al. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice. J. Thromb. Haemost. 21, 2101\u20132113 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"51296_CR83","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"51296_CR84","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nbt.1995","volume":"29","author":"L Ivanciu","year":"2011","unstructured":"Ivanciu, L. et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat. Biotechnol. 29, 1028\u20131033 (2011).","journal-title":"Nat. Biotechnol."},{"key":"51296_CR85","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/blood.V71.3.728.728","volume":"71","author":"T Kumada","year":"1988","unstructured":"Kumada, T., Dittman, W. A. & Majerus, P. W. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 71, 728\u2013733 (1988).","journal-title":"Blood"},{"key":"51296_CR86","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1538-7836.2012.04705.x","volume":"10","author":"CH Miller","year":"2012","unstructured":"Miller, C. H. et al. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J. Thromb. Haemost. 10, 1055\u20131061 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"51296_CR87","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/hae.13435","volume":"24","author":"B Boylan","year":"2018","unstructured":"Boylan, B. & Miller, C. H. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia 24, 487\u2013491 (2018).","journal-title":"Haemophilia"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51296-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:13:24Z","timestamp":1724422404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51296"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51296-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests, Dr. George is on the Scientific Advisory Board of Form Bio and STRM.bio, a consultant for Pfizer, Regeneron, Spark and Tome Biosciences and received licensing fees and research support from Asklepios BioPharmaceutical. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7193"}}